USS Investment Management Ltd Trims Stock Position in Zoetis Inc. $ZTS

Key Points

• USS Investment Management Ltd reduced its stake in Zoetis Inc. by 16.0%, holding 80,104 shares valued at approximately $13.2 million as of the latest filing.
• The company reported $1.76 earnings per share for the recent quarter, surpassing analyst expectations and showing a revenue increase of 4.2% year-over-year.
• According to analyst reports, Zoetis currently has a consensus rating of "Moderate Buy" with an average price target of $202.43.

USS Investment Management Ltd lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 16.0% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,104 shares of the company's stock after selling 15,221 shares during the quarter. USS Investment Management Ltd's holdings in Zoetis were worth $13,187,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ZTS. 1248 Management LLC purchased a new stake in shares of Zoetis during the 1st quarter valued at about $27,000. Saudi Central Bank purchased a new stake in Zoetis in the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC increased its holdings in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after acquiring an additional 120 shares in the last quarter. Finally, Sound Income Strategies LLC increased its holdings in Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after acquiring an additional 164 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 0.0%

Shares of ZTS opened at $153.15 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a 50 day simple moving average of $153.16 and a two-hundred day simple moving average of $157.72. The firm has a market cap of $67.87 billion, a P/E ratio of 26.36, a price-to-earnings-growth ratio of 2.46 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the firm posted $1.56 EPS. The company's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of analyst reports. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Zoetis presently has a consensus rating of "Moderate Buy" and an average price target of $202.43.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.